Investegate |https://immatics.com/ Announcements | https://immatics.com/: Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs · cancer · Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products · Houston, Texas and Tuebingen, Germany, March 17, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a clinical data update from the dose escalation cohorts of the company’s ongoing ...
Source: investegate.co.uk